NeuroScientific Biopharmaceuticals (NSB) Q1 2025 TU earnings summary

Executive summary

• Commenced IND-enabling studies for EmtinB in advanced glaucoma following a pre-IND meeting with the FDA in June 2024.

• Engaged a global bioanalytical lab for in vitro melanin binding studies to inform animal model selection.

• Evaluating new opportunities to expand and enhance the drug development portfolio.

Financial highlights

• Cash balance of A$4.74 million as of 30 September 2024, down from A$4.95 million at the previous quarter end.

• Net cash used in operating activities was A$217k for the quarter.

• Research and development payments were A$37k, staff costs A$67k, and administration/corporate costs A$143k for the quarter.

• Interest income for the quarter was A$30k.

Outlook and guidance

• Net cash burn for the December 2024 quarter expected to be similar to the September 2024 quarter.

• Company continues to define its short-, medium-, and long-term strategy.